 DELRAY BEACH, Fla., Jan. 04, 2021 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. NASDAQ: AZRX, AzurRx or the Company, a company specializing in the development of non-systemic therapies for gastrointestinal GI diseases, today announced that it has signed an exclusive worldwide licensing agreement with First Wave Bio, Inc. First Wave for the use of their patented and proprietary oral and rectal formulations of niclosamide for the treatment of immune checkpoint inhibitor-associated colitis ICI-AC and COVID-19 GI infections. 